Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $RLAY
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/10/2024 | $20.00 | Buy | Goldman |
9/10/2024 | Outperform → Perform | Oppenheimer | |
9/10/2024 | $10.60 → $16.00 | Hold → Buy | Jefferies |
5/10/2024 | $15.00 | Equal Weight → Overweight | Barclays |
4/20/2023 | $12.50 | Underperform → Hold | Jefferies |
4/19/2023 | $29.00 | Outperform → Strong Buy | Raymond James |
4/13/2023 | $29.00 | Outperform | Raymond James |
2/3/2023 | $33.00 | Outperform | Oppenheimer |
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine therapy combinations underway Approximately $780 million in cash, cash equivalents and investments at end of Q4 2024, which will be prioritized to fully fund the execution of the ReDiscover-2 Phase 3 trial
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ETBarclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11:00 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://ir.relaytx.
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay Therapeutics Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the fir
Goldman resumed coverage on Relay Therapeutics with a new price target
Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00
Relay Therapeutics downgraded by Oppenheimer
Oppenheimer downgraded Relay Therapeutics from Outperform to Perform
Relay Therapeutics upgraded by Jefferies with a new price target
Jefferies upgraded Relay Therapeutics from Hold to Buy and set a new price target of $16.00 from $10.60 previously
President and CEO Patel Sanjiv sold $818,400 worth of shares (215,506 units at $3.80) and was granted 332,465 shares, increasing direct ownership by 15% to 883,089 units (SEC Form 4)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
Officer Rahmer Peter sold $204,753 worth of shares (45,464 units at $4.50) and was granted 139,141 shares, increasing direct ownership by 30% to 402,431 units (SEC Form 4)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
Chief Financial Officer Catinazzo Thomas sold $268,339 worth of shares (58,936 units at $4.55) and was granted 139,141 shares, increasing direct ownership by 27% to 379,431 units (SEC Form 4)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
SEC Form SCHEDULE 13G filed by Relay Therapeutics Inc.
SCHEDULE 13G - Relay Therapeutics, Inc. (0001812364) (Subject)
SEC Form S-8 filed by Relay Therapeutics Inc.
S-8 - Relay Therapeutics, Inc. (0001812364) (Filer)
SEC Form 10-K filed by Relay Therapeutics Inc.
10-K - Relay Therapeutics, Inc. (0001812364) (Filer)
Section 32 Raises $740 Million Venture Fund
SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.
Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment of Patrick Riley, Ph.D., as senior vice president of artificial intelligence. Dr. Riley is an industry expert in artificial intelligence and machine learning, bringing 15 years of experience from Google and extensive knowledge in applying these technologies to drug discovery. Dr. Riley will lead a computational team and report to group head, Pat Walters. "We are excited to welcome Patrick to our computational organi
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3C
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE,
Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SEC Form SC 13G filed by Relay Therapeutics Inc.
SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)